Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

无容量 医学 肝细胞癌 打开标签 内科学 肿瘤科 相(物质) 临床试验 免疫疗法 癌症 化学 有机化学
作者
Anthony B. El-Khoueiry,Bruno Sangro,Thomas Yau,Todd S. Crocenzi,Masatoshi Kudo,Chiun Hsu,Tae‐You Kim,Su-Pin Choo,Jörg Trojan,Theodore H. Welling,Tim Meyer,Yoon‐Koo Kang,Winnie Yeo,Akhil Chopra,Jeffrey Anderson,Christine Dela Cruz,Lixin Lang,Jaclyn Neely,Hao Tang,Homa Dastani
出处
期刊:The Lancet [Elsevier BV]
卷期号:389 (10088): 2492-2502 被引量:3959
标识
DOI:10.1016/s0140-6736(17)31046-2
摘要

Summary

Background

For patients with advanced hepatocellular carcinoma, sorafenib is the only approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and efficacy of nivolumab, a programmed cell death protein-1 (PD-1) immune checkpoint inhibitor, in patients with advanced hepatocellular carcinoma with or without chronic viral hepatitis.

Methods

We did a phase 1/2, open-label, non-comparative, dose escalation and expansion trial (CheckMate 040) of nivolumab in adults (≥18 years) with histologically confirmed advanced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection. Previous sorafenib treatment was allowed. A dose-escalation phase was conducted at seven hospitals or academic centres in four countries or territories (USA, Spain, Hong Kong, and Singapore) and a dose-expansion phase was conducted at an additional 39 sites in 11 countries (Canada, UK, Germany, Italy, Japan, South Korea, Taiwan). At screening, eligible patients had Child-Pugh scores of 7 or less (Child-Pugh A or B7) for the dose-escalation phase and 6 or less (Child-Pugh A) for the dose-expansion phase, and an Eastern Cooperative Oncology Group performance status of 1 or less. Patients with HBV infection had to be receiving effective antiviral therapy (viral load <100 IU/mL); antiviral therapy was not required for patients with HCV infection. We excluded patients previously treated with an agent targeting T-cell costimulation or checkpoint pathways. Patients received intravenous nivolumab 0·1–10 mg/kg every 2 weeks in the dose-escalation phase (3+3 design). Nivolumab 3 mg/kg was given every 2 weeks in the dose-expansion phase to patients in four cohorts: sorafenib untreated or intolerant without viral hepatitis, sorafenib progressor without viral hepatitis, HCV infected, and HBV infected. Primary endpoints were safety and tolerability for the escalation phase and objective response rate (Response Evaluation Criteria In Solid Tumors version 1.1) for the expansion phase. This study is registered with ClinicalTrials.gov, number NCT01658878.

Findings

Between Nov 26, 2012, and Aug 8, 2016, 262 eligible patients were treated (48 patients in the dose-escalation phase and 214 in the dose-expansion phase). 202 (77%) of 262 patients have completed treatment and follow-up is ongoing. During dose escalation, nivolumab showed a manageable safety profile, including acceptable tolerability. In this phase, 46 (96%) of 48 patients discontinued treatment, 42 (88%) due to disease progression. Incidence of treatment-related adverse events did not seem to be associated with dose and no maximum tolerated dose was reached. 12 (25%) of 48 patients had grade 3/4 treatment-related adverse events. Three (6%) patients had treatment-related serious adverse events (pemphigoid, adrenal insufficiency, liver disorder). 30 (63%) of 48 patients in the dose-escalation phase died (not determined to be related to nivolumab therapy). Nivolumab 3 mg/kg was chosen for dose expansion. The objective response rate was 20% (95% CI 15–26) in patients treated with nivolumab 3 mg/kg in the dose-expansion phase and 15% (95% CI 6–28) in the dose-escalation phase.

Interpretation

Nivolumab had a manageable safety profile and no new signals were observed in patients with advanced hepatocellular carcinoma. Durable objective responses show the potential of nivolumab for treatment of advanced hepatocellular carcinoma.

Funding

Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
电池小能手完成签到,获得积分20
1秒前
1秒前
文艺的老太完成签到,获得积分10
1秒前
于莹发布了新的文献求助10
1秒前
1秒前
静书完成签到,获得积分10
1秒前
2秒前
黄辉冯完成签到,获得积分10
2秒前
隐形曼青应助友好的麦片采纳,获得10
2秒前
2秒前
2秒前
2秒前
xmuchem发布了新的文献求助10
2秒前
SciGPT应助鳗鱼雪巧采纳,获得10
2秒前
3秒前
3秒前
海棠花未眠完成签到,获得积分10
4秒前
5秒前
5秒前
zz发布了新的文献求助10
5秒前
机智山灵完成签到,获得积分10
5秒前
5秒前
5秒前
麦田里的守望者完成签到,获得积分10
5秒前
124dc发布了新的文献求助10
6秒前
彭于晏应助易酰水烊酸采纳,获得10
6秒前
hjn发布了新的文献求助10
6秒前
orixero应助匆匆而过采纳,获得10
6秒前
6秒前
缚大哥发布了新的文献求助10
7秒前
小梁今天也要努力呀完成签到 ,获得积分10
7秒前
量子星尘发布了新的文献求助10
7秒前
aging00发布了新的文献求助10
8秒前
徐zhipei完成签到 ,获得积分10
8秒前
8秒前
8秒前
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Zur lokalen Geoidbestimmung aus terrestrischen Messungen vertikaler Schweregradienten 1000
Storie e culture della televisione 500
Selected research on camelid physiology and nutrition 500
《2023南京市住宿行业发展报告》 500
Architectural Corrosion and Critical Infrastructure 400
A review of Order Plesiosauria, and the description of a new, opalised pliosauroid, Leptocleidus demoscyllus, from the early cretaceous of Coober Pedy, South Australia 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4890960
求助须知:如何正确求助?哪些是违规求助? 4174608
关于积分的说明 12956124
捐赠科研通 3936644
什么是DOI,文献DOI怎么找? 2159757
邀请新用户注册赠送积分活动 1178149
关于科研通互助平台的介绍 1083632